Inherited Aplastic Anemia

👪

Inheritance

3

Autosomal Recessive

Autosomal Dominant

X-linked

◆

Subtypes

5

Fanconi Anemia

Autosomal recessive (or X-linked) disorder of the FA/BRCA DNA interstrand crosslink repair pathway. Progressive pancytopenia, congenital malformations, and cancer predisposition. More than 2000 cases reported with 22 complementation groups identified.

Show evidence (1 reference)

PMID:20417588 SUPPORT Human Clinical

"the most frequently reported syndrome was FA (2002 cases), followed by Diamond-Blackfan anemia (DBA, 970 cases), Shwachman-Diamond syndrome (SDS, 560 cases), and Dyskeratosis congenita (DC, 550 cases)"

Establishes FA as the most common IBMFS with case report data on relative frequencies of the major subtypes.

Dyskeratosis Congenita (Telomere Biology Disorder)

Telomere biology disorder caused by defects in telomerase or telomere maintenance genes (TERT, TERC, DKC1, TINF2, RTEL1, others). Classical triad of nail dystrophy, oral leukoplakia, and abnormal skin pigmentation.

Show evidence (1 reference)

PMID:39371255 SUPPORT Human Clinical

"altered telomere maintenance as observed in TBDs typically results in premature replicative cellular exhaustion in the respective organ systems eventually leading to life-threatening complications such as bone marrow failure (BMF), pulmonary fibrosis, and liver cirrhosis"

Describes the clinical consequences of telomere biology disorders including bone marrow failure as a primary complication.

Diamond-Blackfan Anemia

Ribosome biogenesis disorder with selective erythroid hypoplasia, congenital anomalies, and cancer predisposition. Most cases involve ribosomal protein gene haploinsufficiency.

Show evidence (1 reference)

PMID:38697731 SUPPORT Human Clinical

"Diamond-Blackfan anaemia (DBA), first described over 80 years ago, is a congenital disorder of erythropoiesis with a predilection for birth defects and cancer"

International consensus statement defining DBA as a congenital erythropoiesis disorder with cancer predisposition.

Shwachman-Diamond Syndrome

Ribosome assembly disorder caused primarily by SBDS mutations, presenting with exocrine pancreatic insufficiency, neutropenia, and skeletal abnormalities.

Show evidence (1 reference)

PMID:36542827 SUPPORT Human Clinical

"Shwachman-Diamond syndrome (SDS) is an inherited multisystem ribosomopathy characterized by exocrine pancreatic deficiency, bone marrow failure, and predisposition to myeloid malignancies"

Defines SDS as a ribosomopathy with the cardinal features of pancreatic deficiency, bone marrow failure, and myeloid malignancy predisposition.

Congenital Amegakaryocytic Thrombocytopenia

Severe thrombocytopenia from birth due to MPL (thrombopoietin receptor) mutations, progressing to pancytopenia and marrow aplasia.

Show evidence (1 reference)

PMID:34404532 SUPPORT Human Clinical

"Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited bone marrow failure syndrome (IBMFS) that is characterized by severe thrombocytopenia at birth due to ineffective megakaryopoiesis and development towards aplastic anemia during the first years of life"

Defines CAMT as an IBMFS with severe thrombocytopenia at birth progressing to aplastic anemia.

⚙

Pathophysiology

7

Defective DNA Damage Repair

The Fanconi anemia pathway repairs DNA interstrand crosslinks through coordinated monoubiquitination of FANCD2/FANCI and recruitment of downstream nucleases and homologous recombination machinery. Loss of any FA pathway component leads to unrepaired DNA damage, chromosomal instability, p53-mediated apoptosis of hematopoietic progenitors, and progressive marrow failure.

Hematopoietic stem cell link

DNA Interstrand Crosslink Repair link DNA Damage Response link

Downstream

Bone Marrow Failure

Show evidence (2 references)

PMID:33058944 SUPPORT In Vitro

"Central to the FA pathway is the monoubiquitination of FANCI-FANCD2 mediated by a ubiquitin RING-E3 ligase complex called the FA core complex. Genetic mutation in any component of the FA core complex results in defective FANCI-FANCD2 monoubiquitination and phenotypes of DNA damage sensitivity,..."

Describes the central role of FANCI-FANCD2 monoubiquitination in the FA DNA repair pathway and the consequences of its disruption.

PMID:34137174 SUPPORT In Vitro

"Fanconi anemia (FA) is a rare genetic disorder caused by mutations in any of the currently 22 known FA genes. The products of these genes, along with other FA-associated proteins, participate in a biochemical pathway, known as the FA pathway. This pathway is responsible for the repair of DNA..."

Establishes that 22 FA genes participate in the ICL repair pathway and that pathway disruption causes genomic instability.

Telomere Attrition

Telomere biology disorders arise from defects in telomerase (TERT, TERC, DKC1), shelterin components (TINF2), or telomere replication helicases (RTEL1). Critically short telomeres trigger replicative senescence and apoptosis preferentially in highly proliferative tissues including hematopoietic stem cells. Telomere length below the first percentile for age is a diagnostic hallmark.

Hematopoietic stem cell link

Telomere Maintenance link Replicative Senescence link

Downstream

Bone Marrow Failure

Show evidence (3 references)

PMID:39371255 SUPPORT Human Clinical

"Premature aging due to critically short telomere length (TL) can also result from pathogenic germline variants in the telomerase complex or related genes that typically counteract replicative telomere shortening in germline and certain somatic cell populations, e.g., hematopoetic stem cells"

Describes how germline variants in telomerase complex genes cause premature telomere shortening particularly in HSCs.

PMID:41904107 SUPPORT Human Clinical

"Telomere biology disorders (TBDs) are a heterogeneous group of inherited systemic diseases caused by pathogenic variants in genes encoding telomerase or proteins involved in telomere maintenance or protection. With very short and/or dysfunctional telomeres, patients with TBD have clinical..."

Confirms that TBD manifestations cluster in highly proliferative tissues due to short/dysfunctional telomeres.

PMID:31647584 SUPPORT Human Clinical

"Assessment of telomere length (TL) in peripheral blood leukocytes is part of the diagnostic algorithm applied to patients with acquired bone marrow failure syndromes (BMFSs) and dyskeratosis congenita (DKC)"

Establishes telomere length assessment as part of the diagnostic workup for bone marrow failure syndromes and dyskeratosis congenita.

Ribosome Biogenesis Defects

Diamond-Blackfan anemia and Shwachman-Diamond syndrome result from defects in ribosomal protein genes or ribosome assembly factors. Impaired ribosome biogenesis activates nucleolar stress, stabilizes p53, and triggers selective apoptosis of erythroid precursors (DBA) or neutrophil precursors (SDS).

Erythroid progenitor cell link Granulocyte monocyte progenitor cell link

Ribosome Biogenesis link

Downstream

Bone Marrow Failure

Show evidence (1 reference)

PMID:36542827 SUPPORT Human Clinical

"The pathobiology of SDS results from impaired ribosomal maturation due to the deficiency of SBDS and the inability to evict the antiassociation factor eIF6 from the 60S ribosomal subunit"

Describes the specific ribosome biogenesis defect in SDS involving SBDS-mediated eIF6 eviction from the 60S subunit.

Impaired Thrombopoietin Signaling

Congenital amegakaryocytic thrombocytopenia results from loss-of-function mutations in MPL (thrombopoietin receptor) or rarely THPO (thrombopoietin ligand). Absent thrombopoietin signaling causes ineffective megakaryopoiesis with severe thrombocytopenia at birth, progressing to pancytopenia and aplastic anemia during early childhood as HSC maintenance is also compromised.

Megakaryocyte progenitor cell link

Thrombopoietin Signaling link

Downstream

Bone Marrow Failure

Show evidence (1 reference)

PMID:34404532 SUPPORT Human Clinical

"CAMT in a narrow sense, which is primarily restricted to the hematopoietic system, is caused mainly by mutations in the gene for the thrombopoietin receptor (MPL), sometimes in the gene for its ligand (THPO)"

Identifies MPL and THPO mutations as causes of CAMT, restricted to the hematopoietic system.

Inflammatory Cytokine-Mediated HSC Suppression

Pro-inflammatory cytokines including TGF-beta, IL-1beta, and IFN-alpha mediate cytopenias across inherited bone marrow failure syndromes. Different germline stresses converge on TP53-dependent growth arrest and apoptosis of hematopoietic stem, progenitor, and precursor cells, with inflammatory cytokines playing a pathogenic role in both cytopenias and transformation to myeloid neoplasia.

Hematopoietic stem cell link

Inflammatory Response link Apoptotic Process link

Downstream

Bone Marrow Failure

Show evidence (1 reference)

PMID:37627314 SUPPORT Human Clinical

"an overarching hypothesis states that different stresses elicit TP53-dependent growth arrest and apoptosis of hematopoietic stem, progenitor, and precursor cells. Here, we review the IBMFSs and propose a role for pro-inflammatory cytokines, such as TGF-β, IL-1β, and IFN-α, in mediating the cytopenias"

Proposes inflammatory cytokines as convergent mediators of cytopenias across all IBMFSs, acting through TP53-dependent growth arrest and apoptosis.

Bone Marrow Failure

Common endpoint of all inherited aplastic anemias: progressive depletion of hematopoietic stem and progenitor cells leading to hypocellular marrow and peripheral cytopenias. The rate of progression and specific lineage involvement vary by underlying genetic defect.

Hematopoietic stem cell link

Hematopoiesis link

Downstream

Clonal Evolution to MDS/AML

Show evidence (2 references)

PMID:20417588 SUPPORT Human Clinical

"The inherited marrow failure syndromes are a diverse set of genetic disorders characterized by hematopoietic aplasia and cancer predisposition. The clinical phenotypes are highly variable and much broader than previously recognized"

Canonical review establishing IBMFSs as genetic disorders of hematopoietic aplasia with variable clinical phenotypes.

PMID:41904107 SUPPORT Human Clinical

"Bone marrow failure (BMF) is the most common hematologic complication of a TBD and can precede the development of more difficult-to-treat malignant transformation"

Confirms that BMF is the most common hematologic complication in TBDs and can precede malignant transformation.

Clonal Evolution to MDS/AML

Chronic replicative stress and genomic instability in the residual HSC compartment select for clones with acquired somatic mutations, commonly involving TP53, RUNX1, and RAS pathway genes. This drives progression to myelodysplastic syndrome and acute myeloid leukemia.

Hematopoietic stem cell link

DNA Damage Response link

Show evidence (3 references)

PMID:36542827 SUPPORT Human Clinical

"Genomic analysis revealed that most myeloid malignancies in patients with SDS have biallelic loss-of-function TP53 mutations. Single-cell DNA sequencing of SDS bone marrow samples can detect premalignant biallelic TP53-mutated clones before clinical diagnosis"

Demonstrates TP53 biallelic inactivation as a key driver of clonal evolution to myeloid malignancy in SDS.

PMID:39357070 SUPPORT Human Clinical

"germline predisposition to myeloid neoplasms is also associated with a wide range of other syndromes, including SAMD9/9L associated predisposition, GATA2 deficiency, RASopathies, ribosomopathies, telomere biology disorders, Fanconi anemia, severe congenital neutropenia, Down syndrome, and others"

Confirms that multiple IBMFSs including FA, TBDs, ribosomopathies, and SCN are recognized germline predispositions to myeloid neoplasms.

PMID:20417588 SUPPORT Human Clinical

"the cumulative incidences of these respective complications were around 50, 25, and 10%"

Reports cumulative incidences of bone marrow failure (~50%), leukemia (~25%), and solid tumors (~10%) in FA.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

14

Blood 5

Pancytopenia VERY_FREQUENT Pancytopenia (HP:0001876)

Show evidence (1 reference)

PMID:20417588 SUPPORT Human Clinical

"Blood pancytopenia was the most common presentation, particularly when the red cell mean cell volume (MCV) and fetal hemoglobin (Hb F) were elevated for age"

Establishes pancytopenia with elevated MCV and HbF as the most common presentation in FA.

Thrombocytopenia VERY_FREQUENT Thrombocytopenia (HP:0001873)

Macrocytic Anemia VERY_FREQUENT Macrocytic anemia (HP:0001972)

Predisposition to MDS/AML FREQUENT Myelodysplasia (HP:0002863)

Show evidence (2 references)

PMID:20417588 SUPPORT Human Clinical

"the risk for AML was more than 600-fold, for HNSCC it was ~500-fold, and for vaginal SCC it was about 3000-fold"

Quantifies the dramatically elevated cancer risks in FA.

PMID:36542827 SUPPORT Human Clinical

"Clinical outcomes for patients with SDS who develop myeloid malignancies are extremely poor because of high treatment-related toxicities and a high rate of refractory disease/relapse even after allogeneic hematopoietic stem cell transplant (HSCT)"

Confirms poor outcomes of myeloid malignancies in SDS.

Neutropenia VERY_FREQUENT Decreased total neutrophil count (HP:0001875)

Show evidence (1 reference)

PMID:20417588 SUPPORT Human Clinical

"several children with malabsorption due to pancreatic insufficiency also had neutropenia"

The original description of SDS was motivated by the co-occurrence of pancreatic insufficiency and neutropenia, establishing neutropenia as a cardinal feature.

Digestive 2

Hepatic Fibrosis OCCASIONAL Hepatic fibrosis (HP:0001395)

Show evidence (1 reference)

PMID:39371255 SUPPORT Human Clinical

"altered telomere maintenance as observed in TBDs typically results in premature replicative cellular exhaustion in the respective organ systems eventually leading to life-threatening complications such as bone marrow failure (BMF), pulmonary fibrosis, and liver cirrhosis"

Lists liver cirrhosis as a life-threatening complication of TBDs.

Exocrine Pancreatic Insufficiency VERY_FREQUENT Exocrine pancreatic insufficiency (HP:0001738)

Show evidence (1 reference)

PMID:36542827 SUPPORT Human Clinical

"Shwachman-Diamond syndrome (SDS) is an inherited multisystem ribosomopathy characterized by exocrine pancreatic deficiency, bone marrow failure, and predisposition to myeloid malignancies"

Identifies exocrine pancreatic deficiency as a cardinal feature of SDS.

Integument 3

Nail Dystrophy VERY_FREQUENT Nail dystrophy (HP:0008404)

Abnormal Skin Pigmentation VERY_FREQUENT Abnormality of skin pigmentation (HP:0001000)

Head and Neck Squamous Cell Carcinoma OCCASIONAL Squamous cell carcinoma (HP:0002860)

Show evidence (1 reference)

PMID:20417588 SUPPORT Human Clinical

"The most common malignancies were AML, head and neck squamous cell carcinoma (SCC), liver tumors, vaginal SCC, and brain tumors"

Lists head and neck SCC as one of the most common malignancies in FA.

Respiratory 1

Pulmonary Fibrosis FREQUENT Pulmonary fibrosis (HP:0002206)

Show evidence (1 reference)

PMID:39371255 SUPPORT Human Clinical

"altered telomere maintenance as observed in TBDs typically results in premature replicative cellular exhaustion in the respective organ systems eventually leading to life-threatening complications such as bone marrow failure (BMF), pulmonary fibrosis, and liver cirrhosis"

Lists pulmonary fibrosis as a life-threatening complication of TBDs.

Growth 1

Short Stature FREQUENT Short stature (HP:0004322)

Show evidence (1 reference)

PMID:20417588 SUPPORT Human Clinical

"Approximately 60% were reported with at least one physical finding. The most common were short stature, as well as café au lait and hyper- and hypo-pigmented areas"

Confirms short stature as the most common physical finding in FA.

Other 2

Oral Leukoplakia VERY_FREQUENT Oral leukoplakia (HP:0002745)

Radial Ray Anomalies FREQUENT Radial ray deficiency (HP:0006433)

Show evidence (1 reference)

PMID:20417588 SUPPORT Human Clinical

"Abnormalities of the radial ray were described in one-third of the cases, all involving the thumb, with 7% absent or hypoplastic radii"

Quantifies radial ray anomalies as present in one-third of FA cases.

🧬

Genetic Associations

9

FANCA (Most common FA complementation group, accounting for 60-70% of cases)

Autosomal Recessive

Show evidence (1 reference)

PMID:20417588 SUPPORT Human Clinical

"FA is a multigenic disorder with 13 genes currently identified"

Establishes FA as a multigenic disorder. FANCA is the most commonly affected gene accounting for 60-70% of cases.

FANCC (Second most common FA gene, especially prevalent in Ashkenazi Jewish population)

Autosomal Recessive

TERT (Telomerase reverse transcriptase catalytic subunit, mutated in autosomal dominant DC and idiopathic aplastic anemia)

Autosomal Dominant

Show evidence (1 reference)

PMID:39371255 SUPPORT Human Clinical

"Premature aging due to critically short telomere length (TL) can also result from pathogenic germline variants in the telomerase complex or related genes"

Confirms that germline variants in telomerase complex genes (including TERT) cause premature telomere shortening and TBD phenotype.

TERC (Telomerase RNA component, mutated in autosomal dominant DC)

Autosomal Dominant

DKC1 (Dyskerin pseudouridine synthase, mutated in X-linked dyskeratosis congenita)

X-linked

TINF2 (Shelterin component, mutated in autosomal dominant DC with severe phenotype)

Autosomal Dominant

RPS19 (Most commonly mutated gene in Diamond-Blackfan anemia, approximately 25% of cases)

Autosomal Dominant

SBDS (Ribosome assembly factor deficiency causes impaired 60S ribosomal subunit maturation)

Autosomal Recessive

Show evidence (1 reference)

PMID:36542827 SUPPORT Human Clinical

"The pathobiology of SDS results from impaired ribosomal maturation due to the deficiency of SBDS and the inability to evict the antiassociation factor eIF6 from the 60S ribosomal subunit"

Defines the molecular mechanism of SBDS deficiency in SDS.

MPL (Thrombopoietin receptor, biallelic mutations cause congenital amegakaryocytic thrombocytopenia)

Autosomal Recessive

💊

Treatments

5

Hematopoietic Stem Cell Transplantation

Action: hematopoietic stem cell transplantation MAXO:0000747

Only curative therapy for the bone marrow failure component. Reduced-intensity conditioning regimens have improved outcomes in FA and DC patients. In TBDs, toxicities of the conditioning regimen can be detrimental to other organs.

Show evidence (2 references)

PMID:41859097 SUPPORT Human Clinical

"Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative modality in eligible IBMF patients but the indications are individualized due to significant transplant-related morbidity, including secondary cancer"

Confirms HSCT as the only curative option for IBMFSs.

PMID:41904107 SUPPORT Human Clinical

"While allogeneic hematopoietic cell transplant (HCT) is curative for BMF in TBD, toxicities of the conditioning regimen can be detrimental to other organs. Balancing the risk of malignant transformation with HCT toxicity is a core challenge for providers who care for patients with TBD-associated BMF"

Describes the transplant dilemma in TBDs where conditioning toxicity must be balanced against malignancy risk.

Androgen Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: oxymetholone ↗ danazol ↗

Oxymetholone and other androgens can temporarily improve blood counts, particularly in FA and TBDs. Androgens may upregulate telomerase activity.

Show evidence (1 reference)

PMID:41904107 SUPPORT Human Clinical

"we review the clinical presentation, pathophysiology, surveillance, and non-HCT treatment of BMF in TBD, including supportive care, androgens, thrombopoietin receptor agonists, and investigational approaches"

Lists androgens as a non-transplant treatment for BMF in TBDs.

Corticosteroid Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: corticosteroid ↗

First-line treatment for Diamond-Blackfan anemia. The 2024 international consensus recommends lowering the maintenance dose to a maximum of 0.3 mg/kg per day.

Show evidence (1 reference)

PMID:38697731 SUPPORT Human Clinical

"These changes include lowering the prednisone maintenance dose to maximum 0·3 mg/kg per day, raising the pre-transfusion haemoglobin to 9-10 g/dL independent of age, recommending early aggressive chelation, broadening indications for haematopoietic stem-cell transplantation"

International consensus for DBA recommending lowered corticosteroid maintenance dose.

Supportive Care

Action: supportive care MAXO:0000950

Transfusion support with iron chelation therapy for transfusion-dependent patients. Growth factor support (G-CSF, EPO) in selected cases.

Cancer Screening

Action: cancer screening MAXO:0000126

Regular screening for MDS/AML and solid tumors given elevated cancer risk across all subtypes. Bone marrow surveillance can detect premalignant clones in SDS.

Show evidence (2 references)

PMID:36542827 SUPPORT Human Clinical

"Registry data indicate that outcomes are improved for patients with SDS who undergo routine bone marrow surveillance and receive an HSCT before developing an overt malignancy"

Demonstrates clinical benefit of routine bone marrow surveillance in SDS.

PMID:38697731 SUPPORT Human Clinical

"recommending systematic clinical surveillance including early colorectal cancer screening"

DBA consensus recommends systematic surveillance including early colorectal cancer screening.

{ }

Source YAML

click to show

name: Inherited Aplastic Anemia
creation_date: "2026-04-22T00:00:00Z"
updated_date: "2026-04-23T00:00:00Z"
description: >-
  Inherited aplastic anemia encompasses a group of genetic bone marrow failure
  syndromes characterized by impaired hematopoiesis leading to peripheral
  cytopenias. Major subtypes include Fanconi anemia (FA), dyskeratosis congenita
  (DC) and other telomere biology disorders (TBDs), Diamond-Blackfan anemia (DBA),
  Shwachman-Diamond syndrome (SDS), and congenital amegakaryocytic thrombocytopenia
  (CAMT). Pathophysiology converges on defective hematopoietic stem cell (HSC)
  maintenance through DNA repair deficiency (FA/BRCA pathway), telomere attrition
  (telomerase and shelterin defects), ribosome biogenesis failure (DBA, SDS), or
  impaired thrombopoietin signaling (CAMT). Patients share elevated risks of
  myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and solid tumors.
  Hematopoietic stem cell transplantation remains the only curative therapy for
  the marrow failure component.
category: Genetic
disease_term:
  preferred_term: inherited aplastic anemia
  term:
    id: MONDO:0001713
    label: inherited aplastic anemia
parents:
- Bone Marrow Failure
- Hereditary Disease
has_subtypes:
- name: Fanconi Anemia
  description: >-
    Autosomal recessive (or X-linked) disorder of the FA/BRCA DNA interstrand
    crosslink repair pathway. Progressive pancytopenia, congenital malformations,
    and cancer predisposition. More than 2000 cases reported with 22 complementation
    groups identified.
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the most frequently reported syndrome was FA (2002 cases), followed by
      Diamond-Blackfan anemia (DBA, 970 cases), Shwachman-Diamond syndrome
      (SDS, 560 cases), and Dyskeratosis congenita (DC, 550 cases)
    explanation: >-
      Establishes FA as the most common IBMFS with case report data on
      relative frequencies of the major subtypes.
- name: Dyskeratosis Congenita
  display_name: Dyskeratosis Congenita (Telomere Biology Disorder)
  description: >-
    Telomere biology disorder caused by defects in telomerase or telomere
    maintenance genes (TERT, TERC, DKC1, TINF2, RTEL1, others). Classical triad
    of nail dystrophy, oral leukoplakia, and abnormal skin pigmentation.
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      altered telomere maintenance as observed in TBDs typically results in
      premature replicative cellular exhaustion in the respective organ systems
      eventually leading to life-threatening complications such as bone marrow
      failure (BMF), pulmonary fibrosis, and liver cirrhosis
    explanation: >-
      Describes the clinical consequences of telomere biology disorders
      including bone marrow failure as a primary complication.
- name: Diamond-Blackfan Anemia
  description: >-
    Ribosome biogenesis disorder with selective erythroid hypoplasia, congenital
    anomalies, and cancer predisposition. Most cases involve ribosomal protein
    gene haploinsufficiency.
  evidence:
  - reference: PMID:38697731
    reference_title: "Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diamond-Blackfan anaemia (DBA), first described over 80 years ago, is a
      congenital disorder of erythropoiesis with a predilection for birth defects
      and cancer
    explanation: >-
      International consensus statement defining DBA as a congenital
      erythropoiesis disorder with cancer predisposition.
- name: Shwachman-Diamond Syndrome
  description: >-
    Ribosome assembly disorder caused primarily by SBDS mutations, presenting with
    exocrine pancreatic insufficiency, neutropenia, and skeletal abnormalities.
  evidence:
  - reference: PMID:36542827
    reference_title: "Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Shwachman-Diamond syndrome (SDS) is an inherited multisystem ribosomopathy
      characterized by exocrine pancreatic deficiency, bone marrow failure, and
      predisposition to myeloid malignancies
    explanation: >-
      Defines SDS as a ribosomopathy with the cardinal features of pancreatic
      deficiency, bone marrow failure, and myeloid malignancy predisposition.
- name: Congenital Amegakaryocytic Thrombocytopenia
  description: >-
    Severe thrombocytopenia from birth due to MPL (thrombopoietin receptor)
    mutations, progressing to pancytopenia and marrow aplasia.
  evidence:
  - reference: PMID:34404532
    reference_title: "Congenital amegakaryocytic thrombocytopenia - Not a single disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited
      bone marrow failure syndrome (IBMFS) that is characterized by severe
      thrombocytopenia at birth due to ineffective megakaryopoiesis and
      development towards aplastic anemia during the first years of life
    explanation: >-
      Defines CAMT as an IBMFS with severe thrombocytopenia at birth
      progressing to aplastic anemia.
prevalence:
- population: Global
  percentage: Rare
  evidence:
  - reference: PMID:41859097
    reference_title: "Established and emerging non-cellular therapies in inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inherited bone marrow failure syndromes (IBMFs) are a molecularly
      heterogeneous group of genetically-determined syndromes with a wide
      spectrum of clinical abnormalities and risk of hematopoietic neoplasia
      and reduced life expectancy. The prevalence is not well established but
      is growing due to the advent of genetic diagnostics
    explanation: >-
      Confirms that IBMFSs are rare but increasingly recognized due to
      improved genetic testing.
inheritance:
- name: Autosomal Recessive
- name: Autosomal Dominant
- name: X-linked
pathophysiology:
- name: Defective DNA Damage Repair
  description: >-
    The Fanconi anemia pathway repairs DNA interstrand crosslinks through
    coordinated monoubiquitination of FANCD2/FANCI and recruitment of downstream
    nucleases and homologous recombination machinery. Loss of any FA pathway
    component leads to unrepaired DNA damage, chromosomal instability, p53-mediated
    apoptosis of hematopoietic progenitors, and progressive marrow failure.
  cell_types:
  - preferred_term: Hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: DNA Interstrand Crosslink Repair
    term:
      id: GO:0036297
      label: interstrand cross-link repair
  - preferred_term: DNA Damage Response
    term:
      id: GO:0006974
      label: DNA damage response
  evidence:
  - reference: PMID:33058944
    reference_title: "The ubiquitination machinery of the Fanconi Anemia DNA repair pathway."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Central to the FA pathway is the monoubiquitination of FANCI-FANCD2
      mediated by a ubiquitin RING-E3 ligase complex called the FA core complex.
      Genetic mutation in any component of the FA core complex results in
      defective FANCI-FANCD2 monoubiquitination and phenotypes of DNA damage
      sensitivity, birth defects, early-onset bone marrow failure and cancer
    explanation: >-
      Describes the central role of FANCI-FANCD2 monoubiquitination in the FA
      DNA repair pathway and the consequences of its disruption.
  - reference: PMID:34137174
    reference_title: "Mechanism, specificity, and function of FANCD2-FANCI ubiquitination and deubiquitination."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Fanconi anemia (FA) is a rare genetic disorder caused by mutations in
      any of the currently 22 known FA genes. The products of these genes, along
      with other FA-associated proteins, participate in a biochemical pathway,
      known as the FA pathway. This pathway is responsible for the repair of
      DNA interstrand cross-links (ICL) and the maintenance of genomic stability
      in response to replication stress
    explanation: >-
      Establishes that 22 FA genes participate in the ICL repair pathway and
      that pathway disruption causes genomic instability.
  downstream:
  - target: Bone Marrow Failure
- name: Telomere Attrition
  description: >-
    Telomere biology disorders arise from defects in telomerase (TERT, TERC, DKC1),
    shelterin components (TINF2), or telomere replication helicases (RTEL1).
    Critically short telomeres trigger replicative senescence and apoptosis
    preferentially in highly proliferative tissues including hematopoietic stem
    cells. Telomere length below the first percentile for age is a diagnostic hallmark.
  cell_types:
  - preferred_term: Hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: Telomere Maintenance
    term:
      id: GO:0000723
      label: telomere maintenance
  - preferred_term: Replicative Senescence
    term:
      id: GO:0090399
      label: replicative senescence
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Premature aging due to critically short telomere length (TL) can also
      result from pathogenic germline variants in the telomerase complex or
      related genes that typically counteract replicative telomere shortening
      in germline and certain somatic cell populations, e.g., hematopoetic
      stem cells
    explanation: >-
      Describes how germline variants in telomerase complex genes cause
      premature telomere shortening particularly in HSCs.
  - reference: PMID:41904107
    reference_title: "Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Telomere biology disorders (TBDs) are a heterogeneous group of inherited
      systemic diseases caused by pathogenic variants in genes encoding
      telomerase or proteins involved in telomere maintenance or protection.
      With very short and/or dysfunctional telomeres, patients with TBD have
      clinical manifestations clustered in tissues with high rates of cell
      proliferation
    explanation: >-
      Confirms that TBD manifestations cluster in highly proliferative tissues
      due to short/dysfunctional telomeres.
  - reference: PMID:31647584
    reference_title: "Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Assessment of telomere length (TL) in peripheral blood leukocytes is
      part of the diagnostic algorithm applied to patients with acquired bone
      marrow failure syndromes (BMFSs) and dyskeratosis congenita (DKC)
    explanation: >-
      Establishes telomere length assessment as part of the diagnostic workup
      for bone marrow failure syndromes and dyskeratosis congenita.
  downstream:
  - target: Bone Marrow Failure
- name: Ribosome Biogenesis Defects
  description: >-
    Diamond-Blackfan anemia and Shwachman-Diamond syndrome result from defects
    in ribosomal protein genes or ribosome assembly factors. Impaired ribosome
    biogenesis activates nucleolar stress, stabilizes p53, and triggers selective
    apoptosis of erythroid precursors (DBA) or neutrophil precursors (SDS).
  cell_types:
  - preferred_term: Erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  - preferred_term: Granulocyte monocyte progenitor cell
    term:
      id: CL:0000557
      label: granulocyte monocyte progenitor cell
  biological_processes:
  - preferred_term: Ribosome Biogenesis
    term:
      id: GO:0042254
      label: ribosome biogenesis
  evidence:
  - reference: PMID:36542827
    reference_title: "Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pathobiology of SDS results from impaired ribosomal maturation due
      to the deficiency of SBDS and the inability to evict the antiassociation
      factor eIF6 from the 60S ribosomal subunit
    explanation: >-
      Describes the specific ribosome biogenesis defect in SDS involving
      SBDS-mediated eIF6 eviction from the 60S subunit.
  downstream:
  - target: Bone Marrow Failure
- name: Impaired Thrombopoietin Signaling
  description: >-
    Congenital amegakaryocytic thrombocytopenia results from loss-of-function
    mutations in MPL (thrombopoietin receptor) or rarely THPO (thrombopoietin
    ligand). Absent thrombopoietin signaling causes ineffective megakaryopoiesis
    with severe thrombocytopenia at birth, progressing to pancytopenia and
    aplastic anemia during early childhood as HSC maintenance is also compromised.
  cell_types:
  - preferred_term: Megakaryocyte progenitor cell
    term:
      id: CL:0000553
      label: megakaryocyte progenitor cell
  biological_processes:
  - preferred_term: Thrombopoietin Signaling
    term:
      id: GO:0038163
      label: thrombopoietin-mediated signaling pathway
  evidence:
  - reference: PMID:34404532
    reference_title: "Congenital amegakaryocytic thrombocytopenia - Not a single disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CAMT in a narrow sense, which is primarily restricted to the
      hematopoietic system, is caused mainly by mutations in the gene for the
      thrombopoietin receptor (MPL), sometimes in the gene for its ligand (THPO)
    explanation: >-
      Identifies MPL and THPO mutations as causes of CAMT, restricted to the
      hematopoietic system.
  downstream:
  - target: Bone Marrow Failure
- name: Inflammatory Cytokine-Mediated HSC Suppression
  description: >-
    Pro-inflammatory cytokines including TGF-beta, IL-1beta, and IFN-alpha mediate
    cytopenias across inherited bone marrow failure syndromes. Different germline
    stresses converge on TP53-dependent growth arrest and apoptosis of hematopoietic
    stem, progenitor, and precursor cells, with inflammatory cytokines playing a
    pathogenic role in both cytopenias and transformation to myeloid neoplasia.
  cell_types:
  - preferred_term: Hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: Apoptotic Process
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:37627314
    reference_title: "The Molecular and Genetic Mechanisms of Inherited Bone Marrow Failure Syndromes: The Role of Inflammatory Cytokines in Their Pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an overarching hypothesis states that different stresses elicit
      TP53-dependent growth arrest and apoptosis of hematopoietic stem,
      progenitor, and precursor cells. Here, we review the IBMFSs and propose
      a role for pro-inflammatory cytokines, such as TGF-β, IL-1β, and IFN-α,
      in mediating the cytopenias
    explanation: >-
      Proposes inflammatory cytokines as convergent mediators of cytopenias
      across all IBMFSs, acting through TP53-dependent growth arrest and
      apoptosis.
  downstream:
  - target: Bone Marrow Failure
- name: Bone Marrow Failure
  description: >-
    Common endpoint of all inherited aplastic anemias: progressive depletion of
    hematopoietic stem and progenitor cells leading to hypocellular marrow and
    peripheral cytopenias. The rate of progression and specific lineage involvement
    vary by underlying genetic defect.
  cell_types:
  - preferred_term: Hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: Hematopoiesis
    term:
      id: GO:0030097
      label: hemopoiesis
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The inherited marrow failure syndromes are a diverse set of genetic
      disorders characterized by hematopoietic aplasia and cancer predisposition.
      The clinical phenotypes are highly variable and much broader than
      previously recognized
    explanation: >-
      Canonical review establishing IBMFSs as genetic disorders of
      hematopoietic aplasia with variable clinical phenotypes.
  - reference: PMID:41904107
    reference_title: "Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bone marrow failure (BMF) is the most common hematologic complication of
      a TBD and can precede the development of more difficult-to-treat
      malignant transformation
    explanation: >-
      Confirms that BMF is the most common hematologic complication in TBDs
      and can precede malignant transformation.
  downstream:
  - target: Clonal Evolution to MDS/AML
- name: Clonal Evolution to MDS/AML
  description: >-
    Chronic replicative stress and genomic instability in the residual HSC
    compartment select for clones with acquired somatic mutations, commonly
    involving TP53, RUNX1, and RAS pathway genes. This drives progression to
    myelodysplastic syndrome and acute myeloid leukemia.
  cell_types:
  - preferred_term: Hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: DNA Damage Response
    term:
      id: GO:0006974
      label: DNA damage response
  evidence:
  - reference: PMID:36542827
    reference_title: "Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genomic analysis revealed that most myeloid malignancies in patients with
      SDS have biallelic loss-of-function TP53 mutations. Single-cell DNA
      sequencing of SDS bone marrow samples can detect premalignant biallelic
      TP53-mutated clones before clinical diagnosis
    explanation: >-
      Demonstrates TP53 biallelic inactivation as a key driver of clonal
      evolution to myeloid malignancy in SDS.
  - reference: PMID:39357070
    reference_title: "Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      germline predisposition to myeloid neoplasms is also associated with a
      wide range of other syndromes, including SAMD9/9L associated
      predisposition, GATA2 deficiency, RASopathies, ribosomopathies, telomere
      biology disorders, Fanconi anemia, severe congenital neutropenia, Down
      syndrome, and others
    explanation: >-
      Confirms that multiple IBMFSs including FA, TBDs, ribosomopathies, and
      SCN are recognized germline predispositions to myeloid neoplasms.
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the cumulative incidences of these respective complications were around
      50, 25, and 10%
    explanation: >-
      Reports cumulative incidences of bone marrow failure (~50%), leukemia
      (~25%), and solid tumors (~10%) in FA.
phenotypes:
- name: Pancytopenia
  category: Hematologic
  description: >-
    Reduction in all three blood cell lineages (erythrocytes, leukocytes,
    platelets) due to progressive bone marrow failure. In FA, blood pancytopenia
    is the most common presentation with elevated MCV and fetal hemoglobin.
  phenotype_term:
    preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blood pancytopenia was the most common presentation, particularly when
      the red cell mean cell volume (MCV) and fetal hemoglobin (Hb F) were
      elevated for age
    explanation: >-
      Establishes pancytopenia with elevated MCV and HbF as the most common
      presentation in FA.
- name: Thrombocytopenia
  category: Hematologic
  description: >-
    Often the earliest hematologic manifestation, particularly in FA and CAMT.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  frequency: VERY_FREQUENT
- name: Macrocytic Anemia
  category: Hematologic
  description: >-
    Macrocytic anemia is characteristic, with elevated fetal hemoglobin
    and elevated erythrocyte adenosine deaminase activity.
  phenotype_term:
    preferred_term: Macrocytic anemia
    term:
      id: HP:0001972
      label: Macrocytic anemia
  frequency: VERY_FREQUENT
- name: Short Stature
  category: Growth
  description: >-
    Present in majority of FA patients and variably in other IBMFSs.
    The most common physical finding reported in FA patients.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  frequency: FREQUENT
  subtype: Fanconi Anemia
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 60% were reported with at least one physical finding. The
      most common were short stature, as well as café au lait and hyper- and
      hypo-pigmented areas
    explanation: >-
      Confirms short stature as the most common physical finding in FA.
- name: Nail Dystrophy
  category: Dermatologic
  description: >-
    Part of the classical triad of dyskeratosis congenita.
  phenotype_term:
    preferred_term: Nail dystrophy
    term:
      id: HP:0008404
      label: Nail dystrophy
  frequency: VERY_FREQUENT
  subtype: Dyskeratosis Congenita
- name: Oral Leukoplakia
  category: Oral
  description: >-
    White patches on oral mucosa, part of the DC classical triad.
  phenotype_term:
    preferred_term: Oral leukoplakia
    term:
      id: HP:0002745
      label: Oral leukoplakia
  frequency: VERY_FREQUENT
  subtype: Dyskeratosis Congenita
- name: Abnormal Skin Pigmentation
  category: Dermatologic
  description: >-
    Reticular skin pigmentation, part of the DC classical triad.
  phenotype_term:
    preferred_term: Abnormal skin pigmentation
    term:
      id: HP:0001000
      label: Abnormality of skin pigmentation
  frequency: VERY_FREQUENT
  subtype: Dyskeratosis Congenita
- name: Predisposition to MDS/AML
  category: Oncologic
  description: >-
    All inherited bone marrow failure syndromes carry elevated risk of
    myelodysplastic syndrome and acute myeloid leukemia. In FA, the relative
    risk for AML is more than 600-fold compared to the general population.
  phenotype_term:
    preferred_term: Myelodysplastic syndrome
    term:
      id: HP:0002863
      label: Myelodysplasia
  frequency: FREQUENT
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the risk for AML was more than 600-fold, for HNSCC it was ~500-fold,
      and for vaginal SCC it was about 3000-fold
    explanation: >-
      Quantifies the dramatically elevated cancer risks in FA.
  - reference: PMID:36542827
    reference_title: "Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical outcomes for patients with SDS who develop myeloid malignancies
      are extremely poor because of high treatment-related toxicities and a
      high rate of refractory disease/relapse even after allogeneic
      hematopoietic stem cell transplant (HSCT)
    explanation: >-
      Confirms poor outcomes of myeloid malignancies in SDS.
- name: Radial Ray Anomalies
  category: Skeletal
  description: >-
    Thumb and radial bone anomalies are characteristic of Fanconi anemia,
    ranging from absent thumbs to triphalangeal thumbs and absent radii.
    Present in approximately one-third of FA cases.
  phenotype_term:
    preferred_term: Radial ray deficiency
    term:
      id: HP:0006433
      label: Radial ray deficiency
  frequency: FREQUENT
  subtype: Fanconi Anemia
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormalities of the radial ray were described in one-third of the
      cases, all involving the thumb, with 7% absent or hypoplastic radii
    explanation: >-
      Quantifies radial ray anomalies as present in one-third of FA cases.
- name: Pulmonary Fibrosis
  category: Pulmonary
  description: >-
    Pulmonary fibrosis is a major non-hematologic complication of telomere
    biology disorders, resulting from critically short telomeres in lung
    epithelial cells.
  phenotype_term:
    preferred_term: Pulmonary fibrosis
    term:
      id: HP:0002206
      label: Pulmonary fibrosis
  frequency: FREQUENT
  subtype: Dyskeratosis Congenita
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      altered telomere maintenance as observed in TBDs typically results in
      premature replicative cellular exhaustion in the respective organ systems
      eventually leading to life-threatening complications such as bone marrow
      failure (BMF), pulmonary fibrosis, and liver cirrhosis
    explanation: >-
      Lists pulmonary fibrosis as a life-threatening complication of TBDs.
- name: Hepatic Fibrosis
  category: Hepatic
  description: >-
    Liver fibrosis and cirrhosis are recognized complications of telomere biology
    disorders, reflecting telomere attrition in hepatocytes.
  phenotype_term:
    preferred_term: Hepatic fibrosis
    term:
      id: HP:0001395
      label: Hepatic fibrosis
  frequency: OCCASIONAL
  subtype: Dyskeratosis Congenita
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      altered telomere maintenance as observed in TBDs typically results in
      premature replicative cellular exhaustion in the respective organ systems
      eventually leading to life-threatening complications such as bone marrow
      failure (BMF), pulmonary fibrosis, and liver cirrhosis
    explanation: >-
      Lists liver cirrhosis as a life-threatening complication of TBDs.
- name: Exocrine Pancreatic Insufficiency
  category: Gastrointestinal
  description: >-
    Cardinal feature of Shwachman-Diamond syndrome, with pancreatic lipomatosis
    replacing normal acinar tissue.
  phenotype_term:
    preferred_term: Exocrine pancreatic insufficiency
    term:
      id: HP:0001738
      label: Exocrine pancreatic insufficiency
  frequency: VERY_FREQUENT
  subtype: Shwachman-Diamond Syndrome
  evidence:
  - reference: PMID:36542827
    reference_title: "Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Shwachman-Diamond syndrome (SDS) is an inherited multisystem ribosomopathy
      characterized by exocrine pancreatic deficiency, bone marrow failure, and
      predisposition to myeloid malignancies
    explanation: >-
      Identifies exocrine pancreatic deficiency as a cardinal feature of SDS.
- name: Neutropenia
  category: Hematologic
  description: >-
    Neutropenia is a hallmark of Shwachman-Diamond syndrome, often present
    from infancy and contributing to recurrent infections.
  phenotype_term:
    preferred_term: Neutropenia
    term:
      id: HP:0001875
      label: Decreased total neutrophil count
  frequency: VERY_FREQUENT
  subtype: Shwachman-Diamond Syndrome
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      several children with malabsorption due to pancreatic insufficiency also
      had neutropenia
    explanation: >-
      The original description of SDS was motivated by the co-occurrence of
      pancreatic insufficiency and neutropenia, establishing neutropenia as a
      cardinal feature.
- name: Head and Neck Squamous Cell Carcinoma
  category: Oncologic
  description: >-
    FA patients have dramatically elevated risk of squamous cell carcinomas of the
    head and neck, with risk further increased after bone marrow transplantation.
  phenotype_term:
    preferred_term: Head and neck squamous cell carcinoma
    term:
      id: HP:0002860
      label: Squamous cell carcinoma
  frequency: OCCASIONAL
  subtype: Fanconi Anemia
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common malignancies were AML, head and neck squamous cell
      carcinoma (SCC), liver tumors, vaginal SCC, and brain tumors
    explanation: >-
      Lists head and neck SCC as one of the most common malignancies in FA.
genetic:
- name: FANCA
  association: Most common FA complementation group, accounting for 60-70% of cases
  gene_term:
    preferred_term: FANCA
    term:
      id: hgnc:3582
      label: FANCA
  inheritance:
  - name: Autosomal Recessive
  variant_origin: GERMLINE
  subtype: Fanconi Anemia
  evidence:
  - reference: PMID:20417588
    reference_title: "Pathophysiology and management of inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FA is a multigenic disorder with 13 genes currently identified
    explanation: >-
      Establishes FA as a multigenic disorder. FANCA is the most commonly
      affected gene accounting for 60-70% of cases.
- name: FANCC
  association: Second most common FA gene, especially prevalent in Ashkenazi Jewish population
  gene_term:
    preferred_term: FANCC
    term:
      id: hgnc:3584
      label: FANCC
  inheritance:
  - name: Autosomal Recessive
  variant_origin: GERMLINE
  subtype: Fanconi Anemia
- name: TERT
  association: Telomerase reverse transcriptase catalytic subunit, mutated in autosomal dominant DC and idiopathic aplastic anemia
  gene_term:
    preferred_term: TERT
    term:
      id: hgnc:11730
      label: TERT
  inheritance:
  - name: Autosomal Dominant
  variant_origin: GERMLINE
  subtype: Dyskeratosis Congenita
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Premature aging due to critically short telomere length (TL) can also
      result from pathogenic germline variants in the telomerase complex or
      related genes
    explanation: >-
      Confirms that germline variants in telomerase complex genes (including
      TERT) cause premature telomere shortening and TBD phenotype.
- name: TERC
  association: Telomerase RNA component, mutated in autosomal dominant DC
  gene_term:
    preferred_term: TERC
    term:
      id: hgnc:11727
      label: TERC
  inheritance:
  - name: Autosomal Dominant
  variant_origin: GERMLINE
  subtype: Dyskeratosis Congenita
- name: DKC1
  association: Dyskerin pseudouridine synthase, mutated in X-linked dyskeratosis congenita
  gene_term:
    preferred_term: DKC1
    term:
      id: hgnc:2890
      label: DKC1
  inheritance:
  - name: X-linked
  variant_origin: GERMLINE
  subtype: Dyskeratosis Congenita
- name: TINF2
  association: Shelterin component, mutated in autosomal dominant DC with severe phenotype
  gene_term:
    preferred_term: TINF2
    term:
      id: hgnc:11824
      label: TINF2
  inheritance:
  - name: Autosomal Dominant
  variant_origin: GERMLINE
  subtype: Dyskeratosis Congenita
- name: RPS19
  association: Most commonly mutated gene in Diamond-Blackfan anemia, approximately 25% of cases
  gene_term:
    preferred_term: RPS19
    term:
      id: hgnc:10402
      label: RPS19
  inheritance:
  - name: Autosomal Dominant
  variant_origin: GERMLINE
  subtype: Diamond-Blackfan Anemia
- name: SBDS
  association: Ribosome assembly factor deficiency causes impaired 60S ribosomal subunit maturation
  gene_term:
    preferred_term: SBDS
    term:
      id: hgnc:19440
      label: SBDS
  inheritance:
  - name: Autosomal Recessive
  variant_origin: GERMLINE
  subtype: Shwachman-Diamond Syndrome
  evidence:
  - reference: PMID:36542827
    reference_title: "Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pathobiology of SDS results from impaired ribosomal maturation due
      to the deficiency of SBDS and the inability to evict the antiassociation
      factor eIF6 from the 60S ribosomal subunit
    explanation: >-
      Defines the molecular mechanism of SBDS deficiency in SDS.
- name: MPL
  association: Thrombopoietin receptor, biallelic mutations cause congenital amegakaryocytic thrombocytopenia
  gene_term:
    preferred_term: MPL
    term:
      id: hgnc:7217
      label: MPL
  inheritance:
  - name: Autosomal Recessive
  variant_origin: GERMLINE
  subtype: Congenital Amegakaryocytic Thrombocytopenia
treatments:
- name: Hematopoietic Stem Cell Transplantation
  description: >-
    Only curative therapy for the bone marrow failure component. Reduced-intensity
    conditioning regimens have improved outcomes in FA and DC patients. In TBDs,
    toxicities of the conditioning regimen can be detrimental to other organs.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
  evidence:
  - reference: PMID:41859097
    reference_title: "Established and emerging non-cellular therapies in inherited bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Allogeneic hematopoietic stem cell transplantation (HSCT) remains the
      only curative modality in eligible IBMF patients but the indications are
      individualized due to significant transplant-related morbidity, including
      secondary cancer
    explanation: >-
      Confirms HSCT as the only curative option for IBMFSs.
  - reference: PMID:41904107
    reference_title: "Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While allogeneic hematopoietic cell transplant (HCT) is curative for
      BMF in TBD, toxicities of the conditioning regimen can be detrimental
      to other organs. Balancing the risk of malignant transformation with
      HCT toxicity is a core challenge for providers who care for patients
      with TBD-associated BMF
    explanation: >-
      Describes the transplant dilemma in TBDs where conditioning toxicity
      must be balanced against malignancy risk.
- name: Androgen Therapy
  description: >-
    Oxymetholone and other androgens can temporarily improve blood counts,
    particularly in FA and TBDs. Androgens may upregulate telomerase activity.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: oxymetholone
      term:
        id: CHEBI:7864
        label: oxymetholone
    - preferred_term: danazol
      term:
        id: CHEBI:4315
        label: danazol
  evidence:
  - reference: PMID:41904107
    reference_title: "Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we review the clinical presentation, pathophysiology, surveillance, and
      non-HCT treatment of BMF in TBD, including supportive care, androgens,
      thrombopoietin receptor agonists, and investigational approaches
    explanation: >-
      Lists androgens as a non-transplant treatment for BMF in TBDs.
- name: Corticosteroid Therapy
  description: >-
    First-line treatment for Diamond-Blackfan anemia. The 2024 international
    consensus recommends lowering the maintenance dose to a maximum of
    0.3 mg/kg per day.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  evidence:
  - reference: PMID:38697731
    reference_title: "Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These changes include lowering the prednisone maintenance dose to
      maximum 0·3 mg/kg per day, raising the pre-transfusion haemoglobin to
      9-10 g/dL independent of age, recommending early aggressive chelation,
      broadening indications for haematopoietic stem-cell transplantation
    explanation: >-
      International consensus for DBA recommending lowered corticosteroid
      maintenance dose.
- name: Supportive Care
  description: >-
    Transfusion support with iron chelation therapy for transfusion-dependent
    patients. Growth factor support (G-CSF, EPO) in selected cases.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Cancer Screening
  description: >-
    Regular screening for MDS/AML and solid tumors given elevated cancer risk
    across all subtypes. Bone marrow surveillance can detect premalignant clones
    in SDS.
  treatment_term:
    preferred_term: cancer screening
    term:
      id: MAXO:0000126
      label: cancer screening
  evidence:
  - reference: PMID:36542827
    reference_title: "Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Registry data indicate that outcomes are improved for patients with SDS
      who undergo routine bone marrow surveillance and receive an HSCT before
      developing an overt malignancy
    explanation: >-
      Demonstrates clinical benefit of routine bone marrow surveillance in SDS.
  - reference: PMID:38697731
    reference_title: "Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      recommending systematic clinical surveillance including early colorectal
      cancer screening
    explanation: >-
      DBA consensus recommends systematic surveillance including early
      colorectal cancer screening.
datasets:

📚

References & Deep Research

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 48 citations 2026-04-22T22:24:43.409008

1. Disease Information

1.1 Concise overview

Inherited aplastic anemia refers to bone marrow failure due to germline (inherited or de novo) variants in genes essential for hematopoietic stem/progenitor cell (HSPC) maintenance. IBMFS are described as “heterogenous” germline disorders characterized by bone marrow failure, often syndrome-specific organ involvement, and usually predisposition to malignancy. (gutierrezrodrigues2023whentoconsider pages 1-2)

1.2 Key identifiers and controlled vocabulary

Ontology / classification items retrievable in-tool: - ICD-11 (WHO) context: Fanconi anemia appears in the ICD-11 Foundation with entity URI http://id.who.int/icd/entity/1500851497 and is placed under the broader MMS linearization label “congenital aplastic anemia (3A70.0)” in one example mapping. (chute2018therenderingof pages 2-4) - MeSH-style identifiers (example from ClinicalTrials.gov record used for terminology mapping): - D000741: Anemia, Aplastic - D000080983: Bone Marrow Failure Disorders (NCT07102849 chunk 2)

Identifiers not fully retrievable with current evidence: MONDO IDs for the umbrella phenotype, Orphanet (ORPHA) codes, and OMIM series entries for all subtypes were not captured by the retrieved texts in this run. This is a limitation of the current tool retrieval set (see “Evidence gaps”). (chute2018therenderingof pages 2-4, NCT07102849 chunk 2)

1.3 Synonyms and alternative names

Inherited bone marrow failure syndromes (IBMFS) (gutierrezrodrigues2023whentoconsider pages 1-2)
Congenital marrow failure / congenital aplastic anemia (ICD-11 context) (chute2018therenderingof pages 2-4)
Telomere biology disorders (TBD) / dyskeratosis congenita spectrum (niewisch2023clinicalmanifestationsof pages 1-1)

1.4 Evidence source type

Most disease-level information here is derived from aggregated disease resources/reviews/consensus-type articles and registry/cohort analyses (e.g., ASH Education Program review, EBMT registry analysis). (gutierrezrodrigues2023whentoconsider pages 1-2, pagliuca2023currentuseof pages 5-9)

2. Etiology

2.1 Disease causal factors (primary)

Inherited aplastic anemia arises from pathogenic germline variants across several mechanistic classes: 1. DNA damage response/repair defects (canonical example: Fanconi anemia) (kawashima2023themolecularand pages 1-2, kawashima2023themolecularand pages 2-4) 2. Telomere maintenance defects (telomere biology disorders / dyskeratosis congenita spectrum) (niewisch2023clinicalmanifestationsof pages 1-1, niewisch2019anupdateon pages 19-24) 3. Ribosome biogenesis/structure defects (e.g., Diamond–Blackfan anemia) (kawashima2023themolecularand pages 1-2, rakotopare2023p53inthe pages 11-12) 4. Other germline predisposition syndromes with marrow failure (e.g., GATA2 deficiency; SAMD9/SAMD9L-related conditions) (gutierrezrodrigues2023whentoconsider pages 4-6, rudelius2023theinternationalconsensus pages 7-9)

2.2 Risk factors

Genetic risk factors (examples; non-exhaustive): - TBD genes found commonly in adult telomere-length screening cohorts include TERC, TERT, RTEL1, CTC1, NHP2, DKC1, USB1. In one prospective adult study, the most frequent pathogenic/likely pathogenic (P/LP) variants were in TERC (9) and TERT (4), with additional P/LP findings in RTEL1 and NHP2. (tometten2023identificationofadult pages 4-6) - In “acquired” aplastic anemia populations, germline variants (including in TERT/TERC) may confer predisposition; a 2024 review summarizes that ~5%–30% of young AA patients may carry IBMFS-associated germline variants. (wang2024germlinevariantsin pages 1-2)

Environmental/triggering factors: For the inherited syndromes, environmental factors are generally not primary “causes,” but exogenous stresses (e.g., genotoxic stress) can interact with underlying defects to exacerbate HSPC loss, and infection/inflammation can be important triggers for progression in predisposition states. (rakotopare2023p53inthe pages 11-12, kawashima2023themolecularand pages 2-4)

2.3 Protective factors

No specific protective germline or environmental factors were identified in the retrieved evidence. This is an evidence gap for this run.

2.4 Gene–environment interactions

The retrieved evidence supports a framework in which external stresses and inflammatory stimuli interact with underlying germline defects to influence marrow failure severity and clonal evolution (e.g., via p53 activation and cytokine-mediated suppression), but the reportable details are largely mechanistic rather than quantitative GxE effect sizes. (kawashima2023themolecularand pages 2-4, rakotopare2023p53inthe pages 11-12)

3. Phenotypes

3.1 Core phenotype (hematologic)

Cytopenias that can be mono-, bi-, or trilineage, often with hypocellular marrow in many IBMFS presentations. (kawashima2023themolecularand pages 1-2, gutierrezrodrigues2023whentoconsider pages 4-6)
In adults, distinguishing inherited from immune marrow failure may be challenging when presentation is atypical or cryptic. (gutierrezrodrigues2023whentoconsider pages 1-2)

Suggested HPO terms (examples; not exhaustive): - Pancytopenia (HP:0001876) - Aplastic anemia (HP:0001915) - Bone marrow hypocellularity (HP:0005528) - Macrocytosis (HP:0002151) (noted as a predictor/feature in inherited contexts) (gutierrezrodrigues2023whentoconsider pages 2-3)

3.2 Syndromic/extra-hematologic phenotypes that raise suspicion

From adult diagnostic guidance, syndrome clues include: - Fanconi anemia: limb and renal abnormalities (gutierrezrodrigues2023whentoconsider pages 1-2) - Telomere biology disorders: pulmonary and liver disease; adults may present with isolated pulmonary/liver/hematologic disease and may lack classic mucocutaneous findings (niewisch2023clinicalmanifestationsof pages 1-1, gutierrezrodrigues2023whentoconsider pages 1-2) - GATA2 deficiency: recurrent atypical infections (gutierrezrodrigues2023whentoconsider pages 1-2) - Shwachman–Diamond syndrome: pancreatic insufficiency (noted as targeted testing trigger) (gutierrezrodrigues2023whentoconsider pages 2-3)

Suggested HPO terms (examples): - Pulmonary fibrosis (HP:0002206) - Hepatic fibrosis/cirrhosis (HP:0001395) - Recurrent infections (HP:0002719) - Exocrine pancreatic insufficiency (HP:0001738)

3.3 Natural history and progression (selected quantitative data)

Fanconi anemia (FA): reported bone marrow failure cumulative incidence 18–83% (risk-group dependent); AML cumulative incidence 15–20% by age 40; MDS cumulative incidence 40% by age 50; markedly elevated relative risks versus general population; high-risk FA subgroup FANCD1/BRCA2 shows AML cumulative incidence 80% by age 10. (rudelius2023theinternationalconsensus pages 7-9)
Shwachman–Diamond syndrome (SDS): registry data suggest ~1% per year progression with cumulative MDS/AML risk ~36% by age 30; another summary notes ~20% clonal/myeloid evolution by age 18. (rudelius2023theinternationalconsensus pages 7-9)
Severe congenital neutropenia (SCN): median MDS/AML incidence ~21% at 15 years after starting G-CSF. (rudelius2023theinternationalconsensus pages 7-9)
Dyskeratosis congenita / TBD: NCI cohort (n=197) cited cumulative leukemia incidence 2% by age 50 and solid cancer 11% by age 50. (rudelius2023theinternationalconsensus pages 7-9)
SAMD9/SAMD9L: germline mutations noted in up to ~18% of non-FA suspected inherited marrow failure cases, often linked to monosomy 7 and MDS/AML progression. (rudelius2023theinternationalconsensus pages 7-9)

3.4 Quality of life impact

No disease-specific QoL instruments or quantitative QoL outcomes were present in the retrieved evidence. This is an evidence gap for this run.

4. Genetic/Molecular Information

4.1 Causal genes and inheritance patterns (high-level)

Inherited marrow failure can be autosomal recessive, autosomal dominant, X-linked, or de novo; autosomal dominant conditions often exhibit variable penetrance and later onset, complicating family-history-based screening. (gutierrezrodrigues2023whentoconsider pages 2-3)

Key gene groups and representative genes (examples drawn from retrieved evidence): - Telomerase/shelterin/telomere replication: TERC, TERT, RTEL1, CTC1, NHP2, DKC1, USB1 (tometten2023identificationofadult pages 4-6) - DNA repair/FA pathway: multiple FANC genes; also BRCA2/FANCD1 high-risk subgroup (rudelius2023theinternationalconsensus pages 7-9) - SAMD9/SAMD9L (gain-of-function; monosomy 7-associated “rescue” events) (rudelius2023theinternationalconsensus pages 7-9) - GATA2 (immunodeficiency/infection-associated marrow failure spectrum) (gutierrezrodrigues2023whentoconsider pages 1-2)

4.2 Pathogenic variants and variant interpretation

A practical adult workflow emphasizes combining functional assays plus germline genetic testing, and careful interpretation of variant allele frequency (VAF) in blood because somatic genetic rescue and clonal hematopoiesis can confound germline inference. Cultured skin fibroblasts are preferred germline tissue controls; buccal swabs are not recommended. (gutierrezrodrigues2023whentoconsider pages 6-7)
In one adult TL-screening protocol, germline-calling cutoffs included VAF >30% (with absolute read thresholds) and ACMG-based variant classification. (tometten2023identificationofadult pages 2-3)

4.3 Modifier genes / epigenetics

Not specifically retrievable in the current evidence set.

5. Environmental Information

This category is generally secondary for inherited etiologies. The retrieved evidence emphasizes that cellular stresses (oxidative stress, UPR, mitochondrial dysfunction) and inflammatory milieu can modulate outcomes and clonal progression in IBMFS. (kawashima2023themolecularand pages 2-4, kawashima2023themolecularand pages 4-6)

6. Mechanism / Pathophysiology

6.1 Unifying causal chain (current understanding)

A convergent model across IBMFS: 1. Primary germline defect (DNA repair, ribosome biogenesis, telomere maintenance) 2. → Cellular stress (DNA damage, telomere attrition, ribosomal stress, oxidative stress) 3. → TP53 (p53) activation with growth arrest/senescence and apoptosis in HSC/HSPC compartments 4. → Cytopenias and marrow failure, with inflammatory cytokines further suppressing hematopoiesis 5. → Clonal selection/evolution under stress and inflammation, increasing risk of MDS/AML and other cancers

This is explicitly proposed as an overarching hypothesis for IBMFS with p53-dependent growth arrest/apoptosis of hematopoietic stem/progenitor/precursor cells. (kawashima2023themolecularand pages 1-2)

6.2 Inflammation and cytokines

A 2023 mechanistic review proposes a pathogenic role for pro-inflammatory cytokines in cytopenias and clonal evolution, explicitly naming TGF-β, IL-1β, and IFN-α as mediators and noting broader inflammatory signatures including IL-6, IL-8, IP-10/CXCL10, IFN-γ, TNF-α, among others, within SASP-like responses. (kawashima2023themolecularand pages 1-2, kawashima2023themolecularand pages 2-4)

6.3 p53 circuitry and cross-syndrome overlap

p53 activation can repress additional telomere- and DNA repair–related genes via promoter binding and DREAM complex-mediated repression, potentially creating positive feedback loops that blur phenotypes across distinct IBMFS categories. (rakotopare2023p53inthe pages 1-2)

6.4 Suggested ontology terms (mechanisms)

GO Biological Process (examples): - DNA damage response (GO:0006974) - Regulation of cell cycle arrest (GO:0071156) - Apoptotic process (GO:0006915) - Cellular senescence (GO:0090398) - Inflammatory response (GO:0006954)

Cell Ontology (CL) terms (examples): - Hematopoietic stem cell (CL:0000037) - Hematopoietic progenitor cell (CL:0008001) - T cell (CL:0000084) (immune injury context when distinguishing acquired AA vs inherited; see diagnostics) (gutierrezrodrigues2023whentoconsider pages 1-2)

7. Anatomical Structures Affected

7.1 Primary site

Bone marrow hematopoietic compartment (UBERON:0002371; conceptual mapping) with primary injury/exhaustion in HSC/HSPC populations. (kawashima2023themolecularand pages 1-2, rakotopare2023p53inthe pages 11-12)

7.2 Multi-organ involvement (not uniform; syndrome-dependent)

Telomere biology disorders: lung and liver involvement common and may dominate adult phenotypes (niewisch2023clinicalmanifestationsof pages 1-1)

8. Temporal Development

Onset can be neonatal/infancy (e.g., DBA/SCN), childhood (e.g., FA/DC), or adult (cryptic TBD, adult-onset IBMFS) depending on genetic architecture and penetrance. (kawashima2023themolecularand pages 1-2, niewisch2023clinicalmanifestationsof pages 1-1)
Adult-onset TBD/IBMFS can be “cryptic” with limited organ involvement; incomplete penetrance, variable expressivity, and anticipation complicate recognition. (niewisch2023clinicalmanifestationsof pages 1-1)

9. Inheritance and Population

9.1 Epidemiology (selected, from retrieved evidence)

A 2023 mechanistic review tabulated estimated incidence per 1,000,000 births/year: - Fanconi anemia 11.4 - Dyskeratosis congenita/telomere disorders 3.8 - Diamond–Blackfan anemia 10.4 - Shwachman–Diamond syndrome 8.5 - Severe congenital neutropenia 4.7 (kawashima2023themolecularand pages 1-2)

9.2 Inheritance patterns

IBMFS can be autosomal recessive, autosomal dominant, X-linked, or de novo; AR tends to earlier onset with higher penetrance, AD tends to later onset with variable penetrance. (gutierrezrodrigues2023whentoconsider pages 2-3)

9.3 How often “acquired” AA hides inherited causes

In an adult-focused ASH Education review, most BMF is classified as immune (>90%), but a CIBMTR retrospective series found ~7% of presumed immune severe aplastic anemia had an undiagnosed IBMFS (about one-third adults). (gutierrezrodrigues2023whentoconsider pages 1-2)
For adult telomere screening: in the AA/PNH referral category, P/LP TBD variants were found in 3/38 (7.9%) NGS-screened individuals (selected after TL filtering). (tometten2023identificationofadult pages 3-4)
A 2024 TBD review states: “approximately 10% of adult patients with clinical BMF” may have a congenital TBD origin, highlighting counseling and donor-selection implications. (rolles2024inheritedtelomerebiology pages 1-2)

10. Diagnostics

10.1 Diagnostic principles

A widely endorsed approach is functional (disease-specific) assays plus germline genetic testing for all new bone marrow failure patients, including adults, because immune aplastic anemia is a diagnosis of exclusion and inherited disorders may be cryptic. (gutierrezrodrigues2023whentoconsider pages 1-2, gutierrezrodrigues2023whentoconsider pages 6-7)

10.2 Specialized assays (high-yield)

Key functional tests and interpretation notes are summarized in the table below.

Category	Item	Summary	Key thresholds / quantitative findings
Definition	Inherited aplastic anemia / IBMFS	Umbrella term for heterogeneous germline disorders characterized by bone marrow failure/cytopenias, syndrome-specific extrahematopoietic features, and usually elevated malignancy risk; distinction from immune marrow failure is essential because treatment response, transplant planning, and family counseling differ (gutierrezrodrigues2023whentoconsider pages 1-2)	In adults, all new-onset BMF patients should be assessed for inherited causes using clinical history, specialized assays, and germline testing (gutierrezrodrigues2023whentoconsider pages 6-7)
Diagnostic assay	Chromosome breakage test (DEB/MMC)	Functional assay for Fanconi anemia; increased chromosome fragility supports FA among inherited marrow failure syndromes (gutierrezrodrigues2023whentoconsider pages 4-6, wang2024germlinevariantsin pages 2-4)	False negatives can occur with somatic reversion or recent chemotherapy; if suspicion remains high, test non-hematopoietic tissue such as cultured fibroblasts (gutierrezrodrigues2023whentoconsider pages 4-6)
Diagnostic assay	Flow-FISH telomere length	Functional in vivo screen for telomere biology disorders/dyskeratosis congenita in patients with aplastic anemia or suggestive phenotypes (gutierrezrodrigues2023whentoconsider pages 4-6, gutierrezrodrigues2023whentoconsider pages 2-3)	TL <1st percentile for age is highly sensitive/specific for TBD; 1st-10th percentile is suggestive; one prospective adult screening study found P/LP TBD variants in 17/76 (22.4%) shortened-TL cases undergoing NGS (gutierrezrodrigues2023whentoconsider pages 4-6, wang2024germlinevariantsin pages 2-4)
Diagnostic assay	Erythrocyte adenosine deaminase (eADA)	Elevated eADA supports Diamond-Blackfan anemia in the differential diagnosis of inherited marrow failure (gutierrezrodrigues2023whentoconsider pages 4-6, gutierrezrodrigues2023whentoconsider pages 2-3)	Used as targeted functional testing when DBA is suspected; interpret with phenotype/genetics rather than as a stand-alone diagnostic test (gutierrezrodrigues2023whentoconsider pages 4-6)
Diagnostic assay	PNH clone testing	Presence of GPI-negative/PNH clone favors immune/acquired aplastic anemia rather than IBMFS (gutierrezrodrigues2023whentoconsider pages 1-2, wang2024germlinevariantsin pages 2-4)	PNH clones are common in immune BMF and very rare in IBMFS; detection of PNH clone >1% is used as a clue against IBMFS in differential diagnosis (gutierrezrodrigues2023whentoconsider pages 3-4, wang2024germlinevariantsin pages 2-4)
Diagnostic assay	6p CN-LOH / 6pLOH	Somatic loss of heterozygosity in the HLA region is an immune-escape marker supporting acquired/immune AA over inherited syndromes (gutierrezrodrigues2023whentoconsider pages 1-2, wang2024germlinevariantsin pages 2-4)	Reported to have almost 100% positive predictive value for acquired AA in one review summary; presence argues against IBMFS as primary diagnosis (wang2024germlinevariantsin pages 2-4)
Epidemiology / diagnostic yield	Presumed immune SAA later found to have IBMFS	Retrospective CIBMTR series identified occult inherited disease among patients initially classified as immune severe aplastic anemia (gutierrezrodrigues2023whentoconsider pages 1-2)	~7% of presumed immune SAA had undiagnosed IBMFS; about one-third of these occult IBMFS cases were adults (gutierrezrodrigues2023whentoconsider pages 1-2)
Treatment outcomes	Androgens in inherited BMF (EBMT cohort)	Largest recent international retrospective cohort of inherited/acquired BMF treated with androgens; inherited cohort mainly Fanconi anemia and dyskeratosis congenita (pagliuca2023currentuseof pages 1-2, pagliuca2023currentuseof pages 4-5)	In inherited BMF at 3 months: CR 8%, PR 29%; 5-year OS 78%, FFS 14%, transplant-free survival 17%; 5-year cumulative incidence of clonal evolution (AML/MDS) 8% (pagliuca2023currentuseof pages 5-9, pagliuca2023currentuseof pages 1-2)
Treatment outcomes	Danazol in telomere disease	Prospective danazol trial in telomere disease showed both hematologic benefit and telomere elongation, supporting androgen use in selected inherited marrow failure patients (nassani2023theroleof pages 4-5, calado2023bonemarrowfailure pages 1-3)	Danazol 800 mg/day: hematologic response in 19/24 (79%) and telomere elongation in all 12/12 evaluable patients at 24 months (nassani2023theroleof pages 4-5)
Practical diagnostic note	Germline confirmation	Blood-based sequencing can be confounded by somatic rescue/clonal hematopoiesis; variant interpretation must consider VAF, phenotype, inheritance, and tissue source (gutierrezrodrigues2023whentoconsider pages 4-6, gutierrezrodrigues2023whentoconsider pages 6-7)	Germline VAF is often ~50% or ~100%, but variants with VAF >30% may still require confirmation in cultured skin fibroblasts or relatives; buccal swabs are not preferred (gutierrezrodrigues2023whentoconsider pages 4-6, gutierrezrodrigues2023whentoconsider pages 6-7)

Table: This table condenses the most actionable concepts for inherited aplastic anemia/inherited bone marrow failure syndromes: umbrella definition, specialized diagnostic assays, and key recent quantitative outcome data. It is useful as a quick-reference summary for knowledge-base curation and clinical differentiation from acquired/immune aplastic anemia.

10.3 Visual evidence: diagnostic algorithm

A diagnostic algorithm for specialized work-up of confirmed bone marrow failure (including chromosome fragility testing and flow-FISH telomere length) is available as Figure 2 in Gutierrez-Rodrigues et al. (ASH Education Program 2023). (gutierrezrodrigues2023whentoconsider media 4ef49e0b)

10.4 Differentiating inherited from immune/acquired AA

Markers that support immune/acquired AA rather than IBMFS include: - PNH clones (GPI-negative cells) (gutierrezrodrigues2023whentoconsider pages 1-2, wang2024germlinevariantsin pages 2-4) - 6p CN-LOH/6pLOH (HLA-region immune escape) reported with very high PPV for acquired AA in one review summary (wang2024germlinevariantsin pages 2-4)

11. Outcome/Prognosis

Prognosis is syndrome- and treatment-dependent, with major determinants including transplant candidacy, organ involvement (TBD), and clonal evolution risk.

Selected quantitative outcomes (therapy-related): - In inherited BMF patients treated with androgens (EBMT cohort), 5-year overall survival 78% but failure-free survival 14%, reflecting limited durability of androgen monotherapy in many inherited cases; 5-year cumulative incidence of AML/MDS clonal evolution 8%. (pagliuca2023currentuseof pages 5-9)

12. Treatment

12.1 Curative therapy: hematopoietic cell transplantation (HCT)

In adult telomere biology disorders, “The only curative option for TBD-related lung, bone marrow, or hepatic disease is organ transplant.” (niewisch2023clinicalmanifestationsof pages 8-9)

Clinical application: accurate inherited diagnosis is critical for: - transplant timing, - reduced-intensity conditioning selection in susceptible syndromes, - and related-donor selection to avoid donor carriers (explicitly emphasized for congenital TBD origin in adult BMF). (rolles2024inheritedtelomerebiology pages 1-2)

12.2 Androgens (real-world implementation)

EBMT/European registry evidence (inherited BMF subgroup): - Early responses at 3 months: complete remission 8%, partial remission 29%. (pagliuca2023currentuseof pages 1-2) - 5-year outcomes: OS 78%, failure-free survival 14%, transplant-free survival 17%. (pagliuca2023currentuseof pages 5-9)

Telomere disease (danazol prospective trial summary as cited in androgen review): - Danazol 800 mg/day: hematologic response 19/24 (79%) at 3 months; “All evaluable 12 patients had a gain in telomere length at 24 months as compared with baseline.” (nassani2023theroleof pages 4-5)

Expert synthesis: an androgen-focused editorial notes that androgens can be considered in inherited cases as a bridge to transplant or when transplant is not possible, but toxicities can be substantial and careful selection is required. (calado2023bonemarrowfailure pages 1-3)

12.3 Emerging/experimental therapies

Clinical translation emphasis in the retrieved evidence includes gene therapy/editing broadly for inherited hematologic disease, but inherited aplastic anemia–specific gene therapy trial evidence was not retrieved as primary outcomes in this run (evidence gap). (No tool-retrieved primary trial outcome papers specific to IBMFS gene therapy were available in the current evidence set.)

12.4 Clinical trials and real-world research infrastructure

An example of an active observational programmatic study in marrow failure is: - NCT07102849 “Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study” (NIH NHLBI), including MeSH-style controlled vocabulary entries (e.g., D000741 Anemia, Aplastic; D000080983 Bone Marrow Failure Disorders). (NCT07102849 chunk 2)

13. Prevention

Primary prevention of inherited aplastic anemia is not generally feasible because etiology is germline; prevention focuses on: - genetic counseling, cascade testing in families, - avoidance of ineffective or harmful therapies (e.g., misapplied immunosuppression in IBMFS), - surveillance for malignancies and organ complications in specific syndromes.

The importance of recognition in adults is highlighted by the estimate that ~10% of adult clinical BMF may have a congenital TBD origin, affecting counseling and donor selection. (rolles2024inheritedtelomerebiology pages 1-2)

14. Other Species / Natural Disease

No naturally occurring non-human disease analogs were retrieved in this run.

15. Model Organisms

The retrieved evidence provides limited, indirect model-organism detail: - Mouse models with constitutively increased p53 activity have been reported to exhibit features of dyskeratosis congenita in the p53/BMFS mechanistic literature, supporting a p53-mediated causal chain, but explicit model descriptions and identifiers were not retrieved here. (rakotopare2023p53inthe pages 1-2)

Recent developments (2023–2024 highlights prioritized)

Adult IBMFS diagnostic emphasis: ASH Education Program 2023 advocates routine consideration of inherited etiologies in adults and a combined functional + genetic approach, including interpretation pitfalls from somatic rescue and tissue selection for germline confirmation. (gutierrezrodrigues2023whentoconsider pages 1-2, gutierrezrodrigues2023whentoconsider pages 6-7)
Quantitative androgen real-world outcomes: EBMT registry analysis (2023) provides large-cohort response and survival estimates for inherited BMF treated with androgens, enabling benchmarking. (pagliuca2023currentuseof pages 5-9, pagliuca2023currentuseof pages 1-2)
Adult telomere screening yields: prospective flow-FISH TL screening with age-modified criteria demonstrates actionable yield of P/LP variants in telomere genes (TERC/TERT dominant), and clarifies referral thresholds and gene distributions. (tometten2023identificationofadult pages 1-2, tometten2023identificationofadult pages 4-6)
Mechanistic consolidation around p53 + inflammatory cytokines: 2023 mechanistic reviews synthesize gene-category convergence on TP53 and cytokine/SASP-mediated marrow suppression and leukemogenesis. (kawashima2023themolecularand pages 1-2, kawashima2023themolecularand pages 2-4)

Evidence gaps and limitations of this tool run

Comprehensive mapping to OMIM IDs, Orphanet ORPHA codes, and MONDO IDs for each specific inherited aplastic anemia entity was not fully retrievable from the obtained texts. (chute2018therenderingof pages 2-4)
Variant-level details such as ClinVar accessions, gnomAD allele frequencies, and specific recurrent pathogenic variants were not available in the retrieved evidence.
Detailed QoL metrics, comprehensive HPO frequency tables, and robust model organism resources were not retrieved.

Key primary/authoritative sources cited (with publication dates and URLs where available)

Gutierrez-Rodrigues F, Patel BA, Groarke EM. When to consider inherited marrow failure syndromes in adults. Hematology ASH Education Program. Dec 2023. https://doi.org/10.1182/hematology.2023000488 (gutierrezrodrigues2023whentoconsider pages 1-2, gutierrezrodrigues2023whentoconsider pages 4-6, gutierrezrodrigues2023whentoconsider pages 6-7)
Wang P et al. Germline variants in acquired aplastic anemia: current knowledge and future perspectives. Haematologica. Jul 2024. https://doi.org/10.3324/haematol.2023.284312 (wang2024germlinevariantsin pages 1-2, wang2024germlinevariantsin pages 2-4)
Pagliuca S et al. Current use of androgens in bone marrow failure disorders (EBMT). Haematologica. May 2023. https://doi.org/10.3324/haematol.2023.282935 (pagliuca2023currentuseof pages 5-9, pagliuca2023currentuseof pages 1-2)
Tometten M et al. Identification of adult patients with classical DC or cryptic TBD by TL screening. HemaSphere. Apr 2023. https://doi.org/10.1097/hs9.0000000000000874 (tometten2023identificationofadult pages 1-2, tometten2023identificationofadult pages 3-4)
Rolles B et al. Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment. Transfus Med Hemother. Jul 2024. https://doi.org/10.1159/000540109 (rolles2024inheritedtelomerebiology pages 1-2)
Rudelius M et al. ICC of hematologic neoplasms with germline predisposition… Virchows Arch. Nov 2023. https://doi.org/10.1007/s00428-022-03447-9 (rudelius2023theinternationalconsensus pages 7-9)
Kawashima N et al. IBMFS mechanisms: role of inflammatory cytokines. Biomolecules. Aug 2023. https://doi.org/10.3390/biom13081249 (kawashima2023themolecularand pages 2-4, kawashima2023themolecularand pages 1-2)
Rakotopare J, Toledo F. p53 in the molecular circuitry of BMFS. Int J Mol Sci. Oct 2023. https://doi.org/10.3390/ijms241914940 (rakotopare2023p53inthe pages 1-2)
Chute CG. Rare diseases in ICD-11 (Fanconi anemia mapping example). J Inherit Metab Dis. Mar 2018. https://doi.org/10.1007/s10545-018-0172-5 (chute2018therenderingof pages 2-4)

References

(gutierrezrodrigues2023whentoconsider pages 1-2): Fernanda Gutierrez-Rodrigues, Bhavisha A. Patel, and Emma M. Groarke. When to consider inherited marrow failure syndromes in adults. Hematology. American Society of Hematology. Education Program, 2023 1:548-555, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000488, doi:10.1182/hematology.2023000488. This article has 12 citations.
(gutierrezrodrigues2023whentoconsider pages 4-6): Fernanda Gutierrez-Rodrigues, Bhavisha A. Patel, and Emma M. Groarke. When to consider inherited marrow failure syndromes in adults. Hematology. American Society of Hematology. Education Program, 2023 1:548-555, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000488, doi:10.1182/hematology.2023000488. This article has 12 citations.
(chute2018therenderingof pages 2-4): Christopher G. Chute. The rendering of human phenotype and rare diseases in icd-11. Journal of Inherited Metabolic Disease, 41:563-569, Mar 2018. URL: https://doi.org/10.1007/s10545-018-0172-5, doi:10.1007/s10545-018-0172-5. This article has 23 citations and is from a peer-reviewed journal.
(NCT07102849 chunk 2): Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study. National Heart, Lung, and Blood Institute (NHLBI). 2025. ClinicalTrials.gov Identifier: NCT07102849
(niewisch2023clinicalmanifestationsof pages 1-1): Marena R. Niewisch, Fabian Beier, and Sharon A. Savage. Clinical manifestations of telomere biology disorders in adults. Hematology. American Society of Hematology. Education Program, 2023 1:563-572, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000490, doi:10.1182/hematology.2023000490. This article has 38 citations.
(pagliuca2023currentuseof pages 5-9): Simona Pagliuca, Austin G. Kulasekararaj, Dirk-Jan Eikema, Brian Piepenbroek, Raheel Iftikhar, Tariq Mahmood Satti, Morag Griffin, Marica Laurino, Alphan Kupesiz, Yves Bertrand, Bruno Fattizzo, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Paola Corti, Erika Massaccesi, Bruno Lioure, Marisa Calabuig, Matthias Klammer, Emel Unal, Depei Wu, Patrice Chevallier, Edouard Forcade, John A. Snowden, Hakan Ozdogu, Antonio Risitano, and Régis Peffault De Latour. Current use of androgens in bone marrow failure disorders: a report from the severe aplastic anemia working party of the european society for blood and marrow transplantation. Haematologica, 109:765-776, May 2023. URL: https://doi.org/10.3324/haematol.2023.282935, doi:10.3324/haematol.2023.282935. This article has 18 citations.
(kawashima2023themolecularand pages 1-2): Nozomu Kawashima, Valentino Bezzerri, and Seth J. Corey. The molecular and genetic mechanisms of inherited bone marrow failure syndromes: the role of inflammatory cytokines in their pathogenesis. Biomolecules, 13:1249, Aug 2023. URL: https://doi.org/10.3390/biom13081249, doi:10.3390/biom13081249. This article has 13 citations.
(kawashima2023themolecularand pages 2-4): Nozomu Kawashima, Valentino Bezzerri, and Seth J. Corey. The molecular and genetic mechanisms of inherited bone marrow failure syndromes: the role of inflammatory cytokines in their pathogenesis. Biomolecules, 13:1249, Aug 2023. URL: https://doi.org/10.3390/biom13081249, doi:10.3390/biom13081249. This article has 13 citations.
(niewisch2019anupdateon pages 19-24): Marena R. Niewisch and Sharon A. Savage. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Review of Hematology, 12:1037-1052, Dec 2019. URL: https://doi.org/10.1080/17474086.2019.1662720, doi:10.1080/17474086.2019.1662720. This article has 205 citations and is from a peer-reviewed journal.
(rakotopare2023p53inthe pages 11-12): Jeanne Rakotopare and Franck Toledo. P53 in the molecular circuitry of bone marrow failure syndromes. International Journal of Molecular Sciences, 24:14940, Oct 2023. URL: https://doi.org/10.3390/ijms241914940, doi:10.3390/ijms241914940. This article has 8 citations.
(rudelius2023theinternationalconsensus pages 7-9): Martina Rudelius, Olga K. Weinberg, Charlotte M. Niemeyer, Akiko Shimamura, and Katherine R. Calvo. The international consensus classification (icc) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia. Virchows Archiv, 482:113-130, Nov 2023. URL: https://doi.org/10.1007/s00428-022-03447-9, doi:10.1007/s00428-022-03447-9. This article has 79 citations and is from a peer-reviewed journal.
(tometten2023identificationofadult pages 4-6): Mareike Tometten, Martin Kirschner, Robert Meyer, Matthias Begemann, Insa Halfmeyer, Margherita Vieri, Kim Kricheldorf, Angela Maurer, Uwe Platzbecker, Markus Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Höchsmann, C. Matthias Wilk, Claas Hinze, Jörg Chromik, Michael Heuser, Michael Kreuter, Steffen Koschmieder, Jens Peter Panse, Susanne Isfort, Ingo Kurth, Tim Henrik Brümmendorf, and Fabian Beier. Identification of adult patients with classical dyskeratosis congenita or cryptic telomere biology disorder by telomere length screening using age-modified criteria. HemaSphere, Apr 2023. URL: https://doi.org/10.1097/hs9.0000000000000874, doi:10.1097/hs9.0000000000000874. This article has 23 citations and is from a peer-reviewed journal.
(wang2024germlinevariantsin pages 1-2): Peicheng Wang, Wanzhi Jiang, Tianyi Lai, Qi Liu, Yingying Shen, Baodong Ye, and Dijiong Wu. Germline variants in acquired aplastic anemia: current knowledge and future perspectives. Haematologica, 109:2778-2789, Jul 2024. URL: https://doi.org/10.3324/haematol.2023.284312, doi:10.3324/haematol.2023.284312. This article has 16 citations.
(gutierrezrodrigues2023whentoconsider pages 2-3): Fernanda Gutierrez-Rodrigues, Bhavisha A. Patel, and Emma M. Groarke. When to consider inherited marrow failure syndromes in adults. Hematology. American Society of Hematology. Education Program, 2023 1:548-555, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000488, doi:10.1182/hematology.2023000488. This article has 12 citations.
(gutierrezrodrigues2023whentoconsider pages 6-7): Fernanda Gutierrez-Rodrigues, Bhavisha A. Patel, and Emma M. Groarke. When to consider inherited marrow failure syndromes in adults. Hematology. American Society of Hematology. Education Program, 2023 1:548-555, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000488, doi:10.1182/hematology.2023000488. This article has 12 citations.
(tometten2023identificationofadult pages 2-3): Mareike Tometten, Martin Kirschner, Robert Meyer, Matthias Begemann, Insa Halfmeyer, Margherita Vieri, Kim Kricheldorf, Angela Maurer, Uwe Platzbecker, Markus Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Höchsmann, C. Matthias Wilk, Claas Hinze, Jörg Chromik, Michael Heuser, Michael Kreuter, Steffen Koschmieder, Jens Peter Panse, Susanne Isfort, Ingo Kurth, Tim Henrik Brümmendorf, and Fabian Beier. Identification of adult patients with classical dyskeratosis congenita or cryptic telomere biology disorder by telomere length screening using age-modified criteria. HemaSphere, Apr 2023. URL: https://doi.org/10.1097/hs9.0000000000000874, doi:10.1097/hs9.0000000000000874. This article has 23 citations and is from a peer-reviewed journal.
(kawashima2023themolecularand pages 4-6): Nozomu Kawashima, Valentino Bezzerri, and Seth J. Corey. The molecular and genetic mechanisms of inherited bone marrow failure syndromes: the role of inflammatory cytokines in their pathogenesis. Biomolecules, 13:1249, Aug 2023. URL: https://doi.org/10.3390/biom13081249, doi:10.3390/biom13081249. This article has 13 citations.
(rakotopare2023p53inthe pages 1-2): Jeanne Rakotopare and Franck Toledo. P53 in the molecular circuitry of bone marrow failure syndromes. International Journal of Molecular Sciences, 24:14940, Oct 2023. URL: https://doi.org/10.3390/ijms241914940, doi:10.3390/ijms241914940. This article has 8 citations.
(tometten2023identificationofadult pages 3-4): Mareike Tometten, Martin Kirschner, Robert Meyer, Matthias Begemann, Insa Halfmeyer, Margherita Vieri, Kim Kricheldorf, Angela Maurer, Uwe Platzbecker, Markus Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Höchsmann, C. Matthias Wilk, Claas Hinze, Jörg Chromik, Michael Heuser, Michael Kreuter, Steffen Koschmieder, Jens Peter Panse, Susanne Isfort, Ingo Kurth, Tim Henrik Brümmendorf, and Fabian Beier. Identification of adult patients with classical dyskeratosis congenita or cryptic telomere biology disorder by telomere length screening using age-modified criteria. HemaSphere, Apr 2023. URL: https://doi.org/10.1097/hs9.0000000000000874, doi:10.1097/hs9.0000000000000874. This article has 23 citations and is from a peer-reviewed journal.
(rolles2024inheritedtelomerebiology pages 1-2): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 20 citations and is from a peer-reviewed journal.
(wang2024germlinevariantsin pages 2-4): Peicheng Wang, Wanzhi Jiang, Tianyi Lai, Qi Liu, Yingying Shen, Baodong Ye, and Dijiong Wu. Germline variants in acquired aplastic anemia: current knowledge and future perspectives. Haematologica, 109:2778-2789, Jul 2024. URL: https://doi.org/10.3324/haematol.2023.284312, doi:10.3324/haematol.2023.284312. This article has 16 citations.
(gutierrezrodrigues2023whentoconsider pages 3-4): Fernanda Gutierrez-Rodrigues, Bhavisha A. Patel, and Emma M. Groarke. When to consider inherited marrow failure syndromes in adults. Hematology. American Society of Hematology. Education Program, 2023 1:548-555, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000488, doi:10.1182/hematology.2023000488. This article has 12 citations.
(pagliuca2023currentuseof pages 1-2): Simona Pagliuca, Austin G. Kulasekararaj, Dirk-Jan Eikema, Brian Piepenbroek, Raheel Iftikhar, Tariq Mahmood Satti, Morag Griffin, Marica Laurino, Alphan Kupesiz, Yves Bertrand, Bruno Fattizzo, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Paola Corti, Erika Massaccesi, Bruno Lioure, Marisa Calabuig, Matthias Klammer, Emel Unal, Depei Wu, Patrice Chevallier, Edouard Forcade, John A. Snowden, Hakan Ozdogu, Antonio Risitano, and Régis Peffault De Latour. Current use of androgens in bone marrow failure disorders: a report from the severe aplastic anemia working party of the european society for blood and marrow transplantation. Haematologica, 109:765-776, May 2023. URL: https://doi.org/10.3324/haematol.2023.282935, doi:10.3324/haematol.2023.282935. This article has 18 citations.
(pagliuca2023currentuseof pages 4-5): Simona Pagliuca, Austin G. Kulasekararaj, Dirk-Jan Eikema, Brian Piepenbroek, Raheel Iftikhar, Tariq Mahmood Satti, Morag Griffin, Marica Laurino, Alphan Kupesiz, Yves Bertrand, Bruno Fattizzo, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Paola Corti, Erika Massaccesi, Bruno Lioure, Marisa Calabuig, Matthias Klammer, Emel Unal, Depei Wu, Patrice Chevallier, Edouard Forcade, John A. Snowden, Hakan Ozdogu, Antonio Risitano, and Régis Peffault De Latour. Current use of androgens in bone marrow failure disorders: a report from the severe aplastic anemia working party of the european society for blood and marrow transplantation. Haematologica, 109:765-776, May 2023. URL: https://doi.org/10.3324/haematol.2023.282935, doi:10.3324/haematol.2023.282935. This article has 18 citations.
(nassani2023theroleof pages 4-5): Momen Nassani, Riad El Fakih, Jakob Passweg, Simone Cesaro, Hazzaa Alzahrani, Ali Alahmari, Carmem Bonfim, Raheel Iftikhar, Amal Albeihany, Constantijn Halkes, Syed Osman Ahmed, Carlo Dufour, and Mahmoud Aljurf. The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1135160, doi:10.3389/fonc.2023.1135160. This article has 18 citations.
(calado2023bonemarrowfailure pages 1-3): Rodrigo T. Calado. Bone marrow failure on steroids: when to use androgens? Haematologica, 109:695-697, Aug 2023. URL: https://doi.org/10.3324/haematol.2023.283564, doi:10.3324/haematol.2023.283564. This article has 3 citations.
(gutierrezrodrigues2023whentoconsider media 4ef49e0b): Fernanda Gutierrez-Rodrigues, Bhavisha A. Patel, and Emma M. Groarke. When to consider inherited marrow failure syndromes in adults. Hematology. American Society of Hematology. Education Program, 2023 1:548-555, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000488, doi:10.1182/hematology.2023000488. This article has 12 citations.
(niewisch2023clinicalmanifestationsof pages 8-9): Marena R. Niewisch, Fabian Beier, and Sharon A. Savage. Clinical manifestations of telomere biology disorders in adults. Hematology. American Society of Hematology. Education Program, 2023 1:563-572, Dec 2023. URL: https://doi.org/10.1182/hematology.2023000490, doi:10.1182/hematology.2023000490. This article has 38 citations.
(tometten2023identificationofadult pages 1-2): Mareike Tometten, Martin Kirschner, Robert Meyer, Matthias Begemann, Insa Halfmeyer, Margherita Vieri, Kim Kricheldorf, Angela Maurer, Uwe Platzbecker, Markus Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Höchsmann, C. Matthias Wilk, Claas Hinze, Jörg Chromik, Michael Heuser, Michael Kreuter, Steffen Koschmieder, Jens Peter Panse, Susanne Isfort, Ingo Kurth, Tim Henrik Brümmendorf, and Fabian Beier. Identification of adult patients with classical dyskeratosis congenita or cryptic telomere biology disorder by telomere length screening using age-modified criteria. HemaSphere, Apr 2023. URL: https://doi.org/10.1097/hs9.0000000000000874, doi:10.1097/hs9.0000000000000874. This article has 23 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

Deep Research

1. Disease Information

1.1 Concise overview

1.2 Key identifiers and controlled vocabulary

1.3 Synonyms and alternative names

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors (primary)

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core phenotype (hematologic)

3.2 Syndromic/extra-hematologic phenotypes that raise suspicion

3.3 Natural history and progression (selected quantitative data)

3.4 Quality of life impact

4. Genetic/Molecular Information

4.1 Causal genes and inheritance patterns (high-level)

4.2 Pathogenic variants and variant interpretation

4.3 Modifier genes / epigenetics

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Unifying causal chain (current understanding)

6.2 Inflammation and cytokines

6.3 p53 circuitry and cross-syndrome overlap

6.4 Suggested ontology terms (mechanisms)

7. Anatomical Structures Affected

7.1 Primary site

7.2 Multi-organ involvement (not uniform; syndrome-dependent)

8. Temporal Development

9. Inheritance and Population

9.1 Epidemiology (selected, from retrieved evidence)

9.2 Inheritance patterns

9.3 How often “acquired” AA hides inherited causes

10. Diagnostics

10.1 Diagnostic principles

10.2 Specialized assays (high-yield)

10.3 Visual evidence: diagnostic algorithm

10.4 Differentiating inherited from immune/acquired AA

11. Outcome/Prognosis

12. Treatment

12.1 Curative therapy: hematopoietic cell transplantation (HCT)

12.2 Androgens (real-world implementation)

12.3 Emerging/experimental therapies

12.4 Clinical trials and real-world research infrastructure

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Recent developments (2023–2024 highlights prioritized)

Evidence gaps and limitations of this tool run

Key primary/authoritative sources cited (with publication dates and URLs where available)